CSS
HZNP

Cubist Systematic Strategies’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Cubist Systematic Strategies’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-9,200
Closed -$1.05M – 4835
2022
Q4 		$1.05M Hold
9,200
– – 0.01% 2392
2022
Q3 		$569K Buy
+9,200
New +$643K ﹤0.01% 3062

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cubist Systematic Strategies's HZNP Position: Q1 2023 in Review

Cubist Systematic Strategies sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 36,181 shares — an estimated $4.12M sold.

Cubist Systematic Strategies first reported a position in HZNP in Q3 2014 and held it in 32 quarters. The position peaked at $13.5M in Q3 2020. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

  • Cubist Systematic Strategies reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 36,181 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $4.12M.
  • Cubist Systematic Strategies first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2014 and held it in 32 quarters.
  • Cubist Systematic Strategies's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $13.5M in Q3 2020.
  • 553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Cubist Systematic Strategies's 13F filing for Q1 2023, filed 15 May 2023.